Chuckle…Novo Nordisk isn’t all about the weight loss drug. It is a diversified pharma Its success will attract rink dink pharmas late to the party like ALT and NRBO That aside, this is an investors market that buys shares of money making companies The best example I can provide is a compare chart going back 3 years of the Russell 2000 (IWM) ETF (mostly flakey share selling operations with no real earnings) and NVO